icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Seroclearance and Could Be a Valuable Endpoint for Early Development HBV Trials
 
 
  AASLD:Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-nave Patients with Chronic Hepatitis B.- (11/01/17)
 
AASLD/2016:Capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus - (11/22/16)
 
Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects - (11/22/16)
 
Reported by Jules Levin
AASLD, Washington DC, USA, October 20-24 2017
 
Filip De Ridder1, Milan J Sonneveld2, Oliver Lenz1, Harry LA Janssen3, Willem Talloen1, Bettina E Hansen2-4
1Janssen Research & Development, Beerse, Belgium; 2Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 3Toronto Centre for Liver disease, Francis Family Liver Clinic, Toronto General Hospital, Toronto, ON, Canada; 4IHPME, University of Toronto, Toronto, ON, Canada

1205171

1205172

1205173

1205174

1205175

1205176

1205177